MX2015012893A - Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. - Google Patents

Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Info

Publication number
MX2015012893A
MX2015012893A MX2015012893A MX2015012893A MX2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A
Authority
MX
Mexico
Prior art keywords
dengue
virus
constructs
compositions
den
Prior art date
Application number
MX2015012893A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
Claire Kinney
Richard M Kinney
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2015012893A publication Critical patent/MX2015012893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones, usos y manufactura de construcciones del virus del dengue y virus del dengue vivos atenuados. En ciertas modalidades, la composición puede incluir, pero no se limita a una composición tetravalente del virus del dengue. En ciertas modalidades, las composiciones pueden incluir construcciones de uno o más serotipos del virus del dengue, tales como las construcciones del virus dengue-1 (DEN-1), el virus dengue-2 (DEN-2), los virus dengue-3 (DEN-3) o dengue-4 (DEN-4). En otras modalidades, en una composición para generar una vacuna contra una o más construcciones de virus del dengue que pueden o no ser subsecuentemente pasadas a células de mamíferos.
MX2015012893A 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. MX2015012893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
PCT/US2014/024603 WO2014150939A2 (en) 2013-03-15 2014-03-12 Compositions and methods for dengue virus chimeric constructs in vaccines

Publications (1)

Publication Number Publication Date
MX2015012893A true MX2015012893A (es) 2016-04-04

Family

ID=50678274

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2015012893A MX2015012893A (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2019003602A MX2019003602A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000353A MX2023000353A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000349A MX2023000349A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000354A MX2023000354A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2019003602A MX2019003602A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000353A MX2023000353A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000349A MX2023000349A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000354A MX2023000354A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Country Status (32)

Country Link
US (5) US9783579B2 (es)
EP (5) EP3689374B1 (es)
JP (2) JP6818548B2 (es)
KR (3) KR102389908B1 (es)
CN (5) CN105451763B (es)
AR (2) AR095598A1 (es)
AU (2) AU2014235476B2 (es)
CA (4) CA3177574A1 (es)
CR (1) CR20150569A (es)
DK (1) DK4129330T3 (es)
DO (1) DOP2015000232A (es)
EC (1) ECSP23013715A (es)
ES (2) ES2965652T3 (es)
FI (2) FI3539565T3 (es)
FR (1) FR22C1064I1 (es)
HK (1) HK1220359A1 (es)
HR (1) HRP20231581T1 (es)
HU (2) HUE061507T2 (es)
LT (1) LT4129330T (es)
MX (5) MX2015012893A (es)
MY (1) MY187796A (es)
NL (1) NL301223I2 (es)
NZ (1) NZ630869A (es)
PE (2) PE20211814A1 (es)
PH (1) PH12015502120A1 (es)
PL (1) PL3539565T3 (es)
PT (1) PT3539565T (es)
SG (3) SG10201913435TA (es)
SI (1) SI4129330T1 (es)
TW (3) TWI733646B (es)
UY (1) UY35489A (es)
WO (1) WO2014150939A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177574A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
AU2016360487C1 (en) * 2015-11-27 2021-07-22 Km Biologics Co., Ltd. Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
SG11201808906RA (en) 2016-04-13 2018-11-29 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
JP2023516009A (ja) 2020-02-27 2023-04-17 タケダ ワクチン，インコーポレイテッド ウイルス調製物から宿主細胞ｄｎａを取り除く方法
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
ES2140418T3 (es) 1991-09-19 2000-03-01 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
DE69624815T2 (de) 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
EP1021544B1 (en) 1997-10-08 2005-12-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Chimeric vaccine against tick-borne encephalitis virus
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
CA2398872C (en) * 2000-02-16 2018-03-20 Richard M. Kinney Avirulent, immunogenic flavivirus chimeras
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
MX2007015872A (es) 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
AU2006257610B2 (en) * 2005-06-17 2012-11-15 Centers For Disease Control And Prevention Dengue serotype 1 attenuated strain
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
CA3004991C (en) * 2006-08-15 2022-08-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of dengue virus vaccine components
WO2009048658A2 (en) 2007-07-13 2009-04-16 Florida Gulf Coast University Optimized dengue virus entry inhibitory peptide (dn81)
AU2009241354B2 (en) * 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MY184428A (en) 2009-06-01 2021-04-01 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
TW201402143A (zh) 2012-06-10 2014-01-16 Inviragen Inc 抗登革熱病毒疫苗之組成物及投藥方法
EP2877208B1 (en) 2012-07-24 2021-05-12 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
CA3177574A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
SG11201808906RA (en) * 2016-04-13 2018-11-29 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11660333B2 (en) 2017-10-16 2023-05-30 Serum Institute Of India Private Limited Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Also Published As

Publication number Publication date
SG10201913435TA (en) 2020-03-30
TW202144573A (zh) 2021-12-01
US20220062375A1 (en) 2022-03-03
CN113637693A (zh) 2021-11-12
EP3689374A1 (en) 2020-08-05
HUS2300022I1 (hu) 2023-08-28
CA3177574A1 (en) 2014-09-25
PT3539565T (pt) 2023-04-12
KR20220054892A (ko) 2022-05-03
SG10201913387XA (en) 2020-02-27
KR20240014580A (ko) 2024-02-01
UY35489A (es) 2014-10-31
AU2014235476B2 (en) 2019-05-16
US20230181682A1 (en) 2023-06-15
KR20160002780A (ko) 2016-01-08
LT4129330T (lt) 2023-12-27
MX2023000354A (es) 2023-02-13
JP2019146594A (ja) 2019-09-05
MX2019003602A (es) 2022-06-27
MX2023000349A (es) 2023-04-24
AU2019216724B2 (en) 2021-03-04
EP4129330A1 (en) 2023-02-08
EP3689374B1 (en) 2022-11-02
EP4129330B1 (en) 2023-09-06
JP2016513970A (ja) 2016-05-19
CA3177572A1 (en) 2014-09-25
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
CN105451763A (zh) 2016-03-30
US20200061151A1 (en) 2020-02-27
MY187796A (en) 2021-10-24
US10449231B2 (en) 2019-10-22
HK1220359A1 (zh) 2017-05-05
CN113637086A (zh) 2021-11-12
MX2023000353A (es) 2023-02-13
AU2014235476A1 (en) 2015-09-24
CA2903231A1 (en) 2014-09-25
HUE061507T2 (hu) 2023-07-28
EP4183411A1 (en) 2023-05-24
TW201945545A (zh) 2019-12-01
WO2014150939A3 (en) 2014-12-31
AU2019216724A1 (en) 2019-09-05
CR20150569A (es) 2016-04-01
TW201516147A (zh) 2015-05-01
BR122021015503A2 (pt) 2021-12-14
US11931399B2 (en) 2024-03-19
BR112015023635A2 (pt) 2018-06-05
SI4129330T1 (sl) 2024-02-29
JP6818548B2 (ja) 2021-01-20
AR095598A1 (es) 2015-10-28
US20140302088A1 (en) 2014-10-09
AR123702A2 (es) 2023-01-04
EP2968516B1 (en) 2022-01-12
FIC20230021I1 (fi) 2023-06-27
KR102389908B1 (ko) 2022-04-26
CN113637694A (zh) 2021-11-12
ES2933970T3 (es) 2023-02-15
NZ630869A (en) 2017-11-24
PL3539565T3 (pl) 2023-09-25
US20170290884A1 (en) 2017-10-12
BR112015023635A8 (pt) 2021-12-14
CN111778263A (zh) 2020-10-16
ECSP23013715A (es) 2023-04-28
KR102626270B1 (ko) 2024-01-19
DK4129330T3 (da) 2023-12-11
US9783579B2 (en) 2017-10-10
SG11201507460PA (en) 2015-10-29
NZ735336A (en) 2021-04-30
EP2968516A2 (en) 2016-01-20
HRP20231581T1 (hr) 2024-03-15
FI3539565T3 (fi) 2023-04-19
PH12015502120A1 (en) 2016-01-25
EP3539565B1 (en) 2023-01-11
WO2014150939A2 (en) 2014-09-25
PE20211814A1 (es) 2021-09-14
BR122021015502A2 (pt) 2021-12-14
EP3539565A1 (en) 2019-09-18
CA3166063A1 (en) 2014-09-25
TWI726312B (zh) 2021-05-01
TWI733646B (zh) 2021-07-21
CN105451763B (zh) 2021-06-18
NL301223I2 (nl) 2023-07-26
DOP2015000232A (es) 2016-02-29
PE20160027A1 (es) 2016-01-28
AU2019216724C1 (en) 2021-08-26
JP7050031B2 (ja) 2022-04-07

Similar Documents

Publication Publication Date Title
PH12015502120A1 (en) Compositions and methods for dengue virus chimeric constructs in vaccines
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
MY192806A (en) Compositions and methods of vaccination against dengue virus in children and young adults
PH12016502431A1 (en) Composition and methods for administration of vaccines against dengue virus
PE20140646A1 (es) Vacuna de virus de dengue inactivado
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
MX2011008988A (es) Derivados de tienopiridina para el tratamiento y prevencion de infecciones por el virus del dengue.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
GEP20237575B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
MX367792B (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
WO2012065105A3 (en) Chimeric flavivirus vaccines
IN2014CN03925A (es)
PH12021550785A1 (en) Virus vaccine
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
EP2504029A4 (en) COMPOSITIONS, METHODS AND USES FOR THE EXPRESSION OF PEPTIDES ASSOCIATED WITH ENTEROBACTERIA
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
CO2021017772A2 (es) Virus del dengue atenuados
EP2435572A4 (en) RECOMBINANT VIRUSES FROM ANTIGEN CHIMERIC TICK-BORNE ENZEPHALITIS VIRUS AND DENGUE VIRUS TYPE 4
MX2011007602A (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus dengue.

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted